Blood Test Predicts Onset of Alzheimer's Disease
|
By LabMedica International staff writers Posted on 22 Jul 2014 |
|
Image: The Luminex 200 System for Multiplex Testing (Photo courtesy of the University of Utah).
A combination of 10 proteins could predict whether individuals would progress from mild cognitive impairment to Alzheimer's disease (AD) within a year has been discovered.
Mild cognitive impairment (MCI) which includes problems with day-to-day memory, attention and language can be an early sign of dementia, but it can also be a symptom of stress or anxiety. About 10% of people with MCI go on to develop dementia within a year, however, apart from regular memory tests, there is currently no reliable way to predict who will and will not be among them.
Scientists at King's College London (UK) working with Proteome Sciences plc (Cobham, UK) analyzed blood samples from 1,148 subjects: 476 with AD, 220 with MCI, and 452 elderly controls with no dementia. The team analyzed 26 proteins in the blood samples and found that 16 linked strongly to brain shrinkage in the MCI and Alzheimer's groups. All candidate proteins were measured using xMAP multiplex bead assays incorporated in 7 MILLIPLEX MAP panels run on the Luminex 200 instrument (Luminex; Austin, TX, USA).
In a secondary analysis they discovered that a combination of 10 proteins could predict whether individuals would progress from MCI to Alzheimer's disease within a year with an accuracy of 87%. They found that the proteins transthyretin (TTR), clusterin, cystatin C, alpha-1-acid glycoprotein (A1AcidG), Intercellular Adhesion Molecule 1 (ICAM1), cytochrome c4 precursor (CC4), pigment epithelium-derived factor (PEDF), alpha 1-antitrypsin (A1AT), Chemokine ligand 5 (RANTES), and Apolipoprotein C-III (ApoC3) plus the Apolipoprotein E (APOE) genotype, had the greatest predictive power.
Abdul Hye, PhD, the lead author of the study said, “The study marks the end of many years' work to find which of the thousands of proteins in the blood were clinically relevant. We now have a set of 10 proteins that can predict whether someone with early symptoms of memory loss, or mild cognitive impairment will develop Alzheimer's disease within a year, with a high level of accuracy.” The study was published on July 10, 2014, in the journal Alzheimer's and Dementia.
Related Links:
King's College London
Proteome Sciences plc
Luminex
.jpg)
Mild cognitive impairment (MCI) which includes problems with day-to-day memory, attention and language can be an early sign of dementia, but it can also be a symptom of stress or anxiety. About 10% of people with MCI go on to develop dementia within a year, however, apart from regular memory tests, there is currently no reliable way to predict who will and will not be among them.
Scientists at King's College London (UK) working with Proteome Sciences plc (Cobham, UK) analyzed blood samples from 1,148 subjects: 476 with AD, 220 with MCI, and 452 elderly controls with no dementia. The team analyzed 26 proteins in the blood samples and found that 16 linked strongly to brain shrinkage in the MCI and Alzheimer's groups. All candidate proteins were measured using xMAP multiplex bead assays incorporated in 7 MILLIPLEX MAP panels run on the Luminex 200 instrument (Luminex; Austin, TX, USA).
In a secondary analysis they discovered that a combination of 10 proteins could predict whether individuals would progress from MCI to Alzheimer's disease within a year with an accuracy of 87%. They found that the proteins transthyretin (TTR), clusterin, cystatin C, alpha-1-acid glycoprotein (A1AcidG), Intercellular Adhesion Molecule 1 (ICAM1), cytochrome c4 precursor (CC4), pigment epithelium-derived factor (PEDF), alpha 1-antitrypsin (A1AT), Chemokine ligand 5 (RANTES), and Apolipoprotein C-III (ApoC3) plus the Apolipoprotein E (APOE) genotype, had the greatest predictive power.
Abdul Hye, PhD, the lead author of the study said, “The study marks the end of many years' work to find which of the thousands of proteins in the blood were clinically relevant. We now have a set of 10 proteins that can predict whether someone with early symptoms of memory loss, or mild cognitive impairment will develop Alzheimer's disease within a year, with a high level of accuracy.” The study was published on July 10, 2014, in the journal Alzheimer's and Dementia.
Related Links:
King's College London
Proteome Sciences plc
Luminex
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
HPV Molecular Test
BD Onclarity HPV Assay
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Latest Clinical Chem. News
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
- Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
- Blood Biomarker May Signal Cognitive Decline Risk a Decade Before Symptoms
- Blood Test Improves Alzheimer’s Diagnosis Across Care Settings
- New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
- Blood Hormone Pattern Distinguishes Endometriosis with High Accuracy
- Blood Test Brings Alzheimer’s Biomarker Assessment to Routine Labs
- Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80
- ADLM Issues Laboratory Guidance for Gender-Diverse Patient Care
- FDA-Approved Test Identifies Low Risk of Large Esophageal Varices in Cirrhosis
- Blood Protein Signature Diagnoses Pediatric IBD and Distinguishes Subtypes
- Blood Test Detects More High-Risk Prostate Cancers Than PSA
- Rapid Blood Test Aids Diagnosis of Acute Ischemic Stroke
Channels
Molecular Diagnostics
view channel
Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
Chemotherapy remains central to treating childhood cancers, yet its toxic effects can injure healthy tissues, and some tumors later relapse or spread. Clinicians have lacked early molecular markers that... Read more
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read more
Immunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read more
Pathology
view channel
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read more
Technology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
Industry
view channel
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more
